EUCTR2020-005826-27-GR进行中（未招募）1 期
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of Belantamab Mafodotin administered in combination with Lenalidomide and Dexamethasone in patients with newly diagnosed multiple myeloma translplant ineligible.
Hellenic Society of Hematology (EAE)0 个研究点目标入组 66 人开始时间: 2021年1月29日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 66
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Participant aged 18 years or older
- •2.Monoclonal plasma cells in the bone marrow =10% or presence of a biopsy proven plasmacytoma and documented MM satisfying at least 1 of the calcium, renal, anemia, bone (CRAB) criteria or biomarkers of malignancy criteria:
- •CRAB criteria:
- •v.Hypercalcemia: serum calcium>0.25 mmol/L (>1 mg/dL) higher than ULN or >2.75 mmol/L(>11 mg/dL)
- •vi.Renal insufficiency: creatinine clearance<40mL/min or serum creatinine>177 µmol/L(>2 mg/dL)
- •vii.Anemia: hemoglobin>2 g/dL below the lower limit of normal or hemoglobin <10 g/dL
- •viii.Bone lesions: 1 or more osteolytic lesions on skeletal radiography, CT, or PET-CT
- •Any 1 or more of the following biomarkers of malignancy:
- •a.Clonal bone marrow plasma cell percentage =60%
- •b.Involved: uninvolved serum FLC ratio =100
- •c. More than 1 focal lesion on MRI studies
- •3.Must have at least ONE aspect of measurable disease, defined as 1 of the following:
- •Urine M-protein excretion=200 mg/24 hrs (=0.2g/24 hrs), or
- •Serum M-protein concentration =0.5 g/dL (=5.0 g/L), or
- •Serum FLC assay: involved FLC level =10 mg/dL (=100 mg/L) and an abnormal serum FLC ratio (<0.26 or >1.65)
- •4.Not a candidate for high-dose chemotherapy with ASCT due to presence of
- •significant comorbid condition(s), such as cardiac, pulmonary or other major organ dysfunction that are likely to have a negative impact on tolerability of high dose
- •chemotherapy with stem cell transplantation. The patients will be assessed with the IMWG frailty index, a scoring system based on age, comorbidities and cognitive and physical conditions, which is recommended by the ESMO guidelines [11]. Patients with IMWG frailty index score 1 or 2 will be considered transplant ineligible. The reason(s) for transplant ineligibility will be collected in the CRFs
- •5.ECOG status of 0-2
- •6.Adequate organ system function as defined by the below laboratory assessments
- •Hematologic:
- •Absolute neutrophil count (ANC) =1.5 X 10^9/L; GCSF use is NOT allowed to reach this level
- •Hemoglobin = 8.0 g/dL; transfusions are permitted
- •Platelet count = 50 x 10^9/L if bone marrow is >50% involved in myeloma Otherwise =75 x 10^9/L; transfusions are NOT allowed to reach this level
- •Total bilirubin =1.5X ULN
- •(Isolated bilirubin =1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%)
- •ALT = 2.5 X ULN
- •eGFR =30 mL/min/1.73 m^2; calculated using the Modified Diet in Renal Disease (MDRD) formula
- •Spot urine (albumin/creatinine ratio) <500 mg/g (56 mg/mmol)
- •Urine Dipstick: Negative trace; if =1+ only eligible if confirmed <500 mg/g [56 mg/mmol] by albumin/creatinine ratio (spot urine from first void)
- •7.Female participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies:
- •A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
- •Is not a woman of childbearing potential (WOCBP)
- •Is a WOCBP and using two methods of reliable birth control (one method that is highly effective and one additional effective [barrier] method), beginning 4 weeks prior to initiating treatment with lenalidomide, during therapy, during dose interruptions and continuing for 4 weeks following discontinuation of lenalidomide treatment. Thereafter, WOCBP participants must use one method of reliable birth control that is highly effective for a further 4 months following discontinuation of
排除标准
- •1.Prior systemic therapy for MM, or smoldering MM (SMM).
- •2.Peripheral neuropathy or neuropathic pain Grade 2 or higher, as defined by the National Cancer Institute , Common Toxicity Criteria for Adverse Events (NCI CTCAE) version 5.
- •3.Major surgery within 4 weeks before the first dose of study drug.
- •4.Presence of active renal condition (infection, requirement for dialysis or any other significant condition that could affect the participant’s safety). Participants with isolated proteinuria resulting from MM are eligible, provided that they fulfil the other inclusion criteria.
- •5.Any serious and/or unstable pre-existing medical or, psychiatric disorder or other conditions (including laboratory abnormalities) that could interfere with participant’s safety, obtaining informed consent or compliance with the study procedures.
- •6.Evidence of active mucosal or internal bleeding uncontrolled by local therapy and not explained by reversible coagulopathy.
- •7.Current active liver or biliary disease (except for Gilbert’s syndrome or asymptomatic gallstones, or otherwise stable chronic liver disease as per the Investigator’s assessment).
- •8.Participants with previous or concurrent malignancies other than multiple myeloma. Exceptions are surgically treated cervical carcinoma in situ, or any other malignancy that has been considered medically stable for at least 2 years. The participant must not be receiving active therapy, other than hormonal therapy for this disease.
- •9.Evidence of cardiovascular risk including any of the following:
- •Evidence of current clinically significant untreated arrhythmias, including clinically significant ECG abnormalities, second degree (Mobitz Type II) or third degree atrioventricular (AV) block.
- •History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting or bypass grafting within 3 months of Screening.
- •10.Class III or IV heart failure as defined by the New York Heart Association functional classification system.
- •11.Uncontrolled hypertension.
- •12.Active infection requiring treatment.
- •13.Known human immunodeficiency virus HIV infection, unless the participant can meet all of the following criteria:
- •Established anti-retroviral therapy (ART) for at least 4 weeks and HIV viral load <400 copies/mL.
- •CD4+ T-cell (CD4+) counts =350 cells/uL.
- •No history of AIDS-defining opportunistic infections within the last 12 months.
- •14. Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]).
- •15.Positive hepatitis C antibody test result or positive hepatitis C RNA test result at screening or within 3 months before the first dose of the study treatment unless the participant can meet the following criteria:
- •RNA test negative
- •Successful anti-viral treatment (usually 8 weeks duration) is required, followed by a negative hepatitis c virus (HCV) RNA test after a washout period of at least 4 weeks.
- •16.Current corneal epithelial disease except for mild punctate keratopathy.
- •17.Intolerance or contraindications to anti-viral prophylaxis.
- •18.Unable to tolerate antithrombotic prophylaxis.
- •19.AL amyloidosis (light chain amyloidosis), active POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal plasma proliferative disorder, skin changes) or active plasma cell leukemia at the time of screening.
- •20.Exhibiting clinical signs of or with a known history of meningeal or central nervous system involvement by multiple myeloma.
- •21.Known i
研究者
相似试验
招募中
1 期
A phase 1/2, dose and schedule evaluation study to investigate the safety and clinical activity of belantamab mafodotin administered in combination with lenalidomide, dexamethasone and nirogacestat in patients with transplant ineligible newly diagnosed multiple myelomaewly diagnosed patients with multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2022-001942-39-GRHellenic Society of Hematology (EAE)36
进行中（未招募）
1 期
Belantamab Mafodotin in combination with Daratumumab, Lenalidomide and Dexamethasone for the treatment of patients with newly diagnosed multiple myeloma transplant ineligible.newly diagnosed multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2021-006792-42-GRHellenic Society of Hematology (EAE)36
招募中
1 期
A PHASE 1/2, DOSE AND SCHEDULE EVALUATION STUDY TO INVESTIGATE THE SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN ADMINISTERED IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE WITH OR WITHOUT DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA PREVIOUSLY TREATED WITH ONE TO THREE LINES OF THERAPY WHO ARE LENALIDOMIDE REFRACTORYRelapsed/refractory multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2022-001941-19-GRHellenic Society of Hematology (EAE)60
尚未招募
1 期
DREAMM-9: Phase 1 Study of Belantamab Mafodotin Plus Standard of care in NewlyDiagnosed Multiple Myeloma patientsCTRI/2024/03/064587GlaxoSmithKline Research Development Limited
进行中（未招募）
1 期
A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours.ocally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC).MedDRA version: 20.0Level: LLTClassification code 10007050Term: CancerSystem Organ Class: 100000004864EUCTR2016-000877-19-GBStarpharma Pty Ltd.65